Published in Cancer Weekly, February 12th, 2008
"Two separate dose-escalating arms (arm A and arm B) were conducted simultaneously. Patients received pemetrexed on day 1 (D1) (500-600 mg/m(2) IV) every 21 days. In arm A, bortezomib was given twice weekly (0.7-1.3 mg/m(2) on D1, 4, 8, and 11). In arm B, bortezomib was given weekly (1.0-1.6 mg/m(2) on D1 and 8). We treated 27 patients on four dose levels in arm A...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.